Catalyst Wire Dossier Catalyst Wire Dossier

Belzutifan

belzutifan · Merck Sharp & Dohme LLC
Drug timelines are a Plus or Pro feature.

16 regulatory and trial events tracked for Belzutifan, covering 2024-02-28 to 2026-04-27. Get the full timeline:

Most recent: Clinical Trial Update: A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033) [Phase 3]

See pricing